Back to today’s briefing

Story perspectives

Sarepta Therapeutics Shares Dive 34% Amid Safety Concerns

6/17/2025

30 2

Summary

Story summary

Sarepta Therapeutics is reeling as its shares plummeted 34% after a second patient tragically succumbed to acute liver failure tied to its gene therapy, Elevidys, aimed at treating Duchenne muscular dystrophy. In response, the company has halted shipments for non-ambulatory patients and paused trials, raising serious safety concerns among analysts about the future of Elevidys.

1 of 1

Story summary

Sarepta Therapeutics is reeling as its shares plummeted 34% after a second patient tragically succumbed to acute liver failure tied to its gene therapy, Elevidys, aimed at treating Duchenne muscular dystrophy. In response, the company has halted shipments for non-ambulatory patients and paused trials, raising serious safety concerns among analysts about the future of Elevidys.